Trial · NCT03614728
Participant flow24
How many started, completed or left each group, period by period.
1 to 20 of 24
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Part 1 (Up to 30.8 Months) | STARTED | Part 1: GSK3326595 400 mg | 13 | |
| Part 1 (Up to 30.8 Months) | STARTED | Part 1: GSK3326595 300 mg | 17 | |
| Part 1 (Up to 30.8 Months) | STARTED | Part 2-Dose Escalation: GSK3326595+5-Azacitidine | 0 | |
| Part 1 (Up to 30.8 Months) | STARTED | Part 2-Dose Expansion: GSK3326595+5-Azacitidine | 0 | |
| Part 1 (Up to 30.8 Months) | COMPLETED | Part 1: GSK3326595 400 mg | 12 | |
| Part 1 (Up to 30.8 Months) | COMPLETED | Part 1: GSK3326595 300 mg | 16 | |
| Part 1 (Up to 30.8 Months) | COMPLETED | Part 2-Dose Escalation: GSK3326595+5-Azacitidine | 0 | |
| Part 1 (Up to 30.8 Months) | COMPLETED | Part 2-Dose Expansion: GSK3326595+5-Azacitidine | 0 | |
| Part 1 (Up to 30.8 Months) | NOT COMPLETED | Part 1: GSK3326595 400 mg | 1 | |
| Part 1 (Up to 30.8 Months) | NOT COMPLETED | Part 1: GSK3326595 300 mg | 1 | |
| Part 1 (Up to 30.8 Months) | NOT COMPLETED | Part 2-Dose Escalation: GSK3326595+5-Azacitidine | 0 | |
| Part 1 (Up to 30.8 Months) | NOT COMPLETED | Part 2-Dose Expansion: GSK3326595+5-Azacitidine | 0 | |
| Part 2 (Up to 3 Years and 2 Months) | STARTED | Part 1: GSK3326595 400 mg | 0 | |
| Part 2 (Up to 3 Years and 2 Months) | STARTED | Part 1: GSK3326595 300 mg | 0 | |
| Part 2 (Up to 3 Years and 2 Months) | STARTED | Part 2-Dose Escalation: GSK3326595+5-Azacitidine | 0 | |
| Part 2 (Up to 3 Years and 2 Months) | STARTED | Part 2-Dose Expansion: GSK3326595+5-Azacitidine | 0 | |
| Part 2 (Up to 3 Years and 2 Months) | COMPLETED | Part 1: GSK3326595 400 mg | 0 | |
| Part 2 (Up to 3 Years and 2 Months) | COMPLETED | Part 1: GSK3326595 300 mg | 0 | |
| Part 2 (Up to 3 Years and 2 Months) | COMPLETED | Part 2-Dose Escalation: GSK3326595+5-Azacitidine | 0 | |
| Part 2 (Up to 3 Years and 2 Months) | COMPLETED | Part 2-Dose Expansion: GSK3326595+5-Azacitidine | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03614728/flow